About Us
GENPROTIC Biopharma (GB) Pvt. Ltd, founded in January 2020 in Chennai, India, is a pioneering venture dedicated to advancing healthcare through innovative biosimilar drugs. With a strong emphasis on molecular and genetic engineering, GB leverages cutting-edge technology to develop a diverse range of products aimed at addressing critical medical needs.
GB boasts a team of highly skilled experts proficient in various aspects of biopharmaceutical development, including cloning, protein expression, upstream and downstream processes, and analytical characterization. The company's robust infrastructure includes state-of-the-art molecular biology, upstream, downstream, and analytical laboratories, facilitating comprehensive research and development capabilities.
Mission
At Genprotic biopharma, our mission is to harness the power of advanced technology and scientific expertise to develop next-generation biosimilar drugs and molecular diagnostic solutions. We are committed to addressing pressing medical challenges.
Vision
To lead the forefront of biopharmaceutical innovation, utilizing cutting-edge molecular diagnostics and genetic engineering to revolutionize global healthcare delivery.
Dr. P. Suthakaran, Founder - Technical
Dr. P. Suthakaran is an esteemed biotechnologist with over 16 years of experience spanning research and industry. Holding an M.Tech in Biotechnology and a Ph.D. in Genetic Engineering from the prestigious Anna University, India, Dr. Suthakaran specializes in recombinant protein production, focusing on optimizing strategies to enhance biological efficacy.
Before establishing GENPROTIC Biopharma, Dr. Suthakaran held pivotal roles as a senior scientist at Anthem Biosciences Pvt Ltd, Bangalore, and as a post-doctoral research fellow at Sun Yat Sen University, China. With a notable track record, he has excelled in scaling up fermentation processes for a wide array of therapeutic and non-therapeutic recombinant proteins.
Dr. Suthakaran's expertise underscores his commitment to adhering to international standards of excellence in biotechnology. His contributions have significantly advanced the field, positioning him as a leader in the global biopharmaceutical landscape.